A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

  • STATUS
    Recruiting
  • End date
    Sep 23, 2021
  • participants needed
    375
  • sponsor
    Eli Lilly and Company
Updated on 17 January 2021
Investigator
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Primary Contact
Diablo Clinical Research (4.7 mi away) Contact
+127 other location
insulin
body mass index
type 2 diabetes mellitus
metformin
hemoglobin a1c
drug test
angiotensin converting enzyme
sglt2

Summary

The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes.

Details
Treatment insulin degludec, LY3209590
Clinical Study IdentifierNCT04450394
SponsorEli Lilly and Company
Last Modified on17 January 2021

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 75 yrs?
Gender: Male or Female
Do you have any of these conditions: Diabetes Mellitus Types I and II or Diabetes Mellitus, Type 2 or Diabetes Mellitus or Diabetes Mellitus Type 2 or NIDDM or Diabetes Prevention or Diab...?
Do you have any of these conditions: noninsulin-dependent diabetes mellitus or diabetes type 2 or NIDDM or type ii diabetes or Diabetes Mellitus, Type 2 or Diabetes Prevention or Diabetes...?
Do you have any of these conditions: Diabetes Mellitus Types I and II or Diabetes Mellitus, Type 2 or Diabetes Mellitus or Diabetes Mellitus Type 2 or diabetes type 2 or type 2 diabetes m...?
Do you have any of these conditions: Diabetes Mellitus or Diabetes (Pediatric) or type ii diabetes or Diabetes Mellitus, Type 2 or type 2 diabetes or type 2 diabetes mellitus or Diabetes ...?
Do you have any of these conditions: Diabetes Mellitus Type 2 or type ii diabetes or type 2 diabetes mellitus or Diabetes (Pediatric) or noninsulin-dependent diabetes mellitus or Diabetes...?
Do you have any of these conditions: type ii diabetes or Diabetes Prevention or type 2 diabetes or NIDDM or Diabetes Mellitus Types I and II or noninsulin-dependent diabetes mellitus or D...?
Do you have any of these conditions: Diabetes Mellitus or Diabetes Mellitus Types I and II or diabetes type 2 or Diabetes (Pediatric) or noninsulin-dependent diabetes mellitus or Diabetes...?
Do you have any of these conditions: Diabetes Mellitus or Diabetes Mellitus Types I and II or diabetes type 2 or Diabetes Mellitus, Type 2 or NIDDM or Diabetes Prevention or Diabetes Mell...?
Do you have any of these conditions: type ii diabetes or type 2 diabetes mellitus or type 2 diabetes or NIDDM or Diabetes Mellitus Types I and II or diabetes type 2 or Diabetes Prevention...?
Participants must have type 2 diabetes mellitus according to the World Health Organization (WHO) criteria treated with a stable dose of metformin in combination with a stable dose of Dipeptidyl Peptidase IV (DPPIV) inhibitor and/or a Sodium-glucose co-transporter-2 (SGLT2) inhibitor for at least 3 months prior to screening
Participants must have a HbA1c value of 7.0% to 9.5%, inclusive
Participants must have a body mass index (BMI) between 20 and 45 kilograms per meter squared (kg/m), inclusive

Exclusion Criteria

Have type 1 diabetes mellitus or latent autoimmune diabetes
Have any episodes of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to screening
Have any of the following cardiovascular (CV) conditions: acute myocardial infarction, New York Heart Association Class III or IV heart failure, or cerebrovascular accident (stroke)
Have acute or chronic hepatitis, or obvious clinical signs or symptoms of any other liver disease
Have an estimated glomerular filtration rate (eGFR) <30 milliliters/minute/1.73 m
Have active or untreated cancer
Are receiving chronic (>14 days) systemic glucocorticoid therapy
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet